Page last updated: 2024-09-04

sodium salicylate and Lymphoma, Primary Effusion

sodium salicylate has been researched along with Lymphoma, Primary Effusion in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hattori, S; Kariya, R; Matsuda, K; Mitchai, M; Okada, S; Srikoon, P; Vaeteewoottacharn, K; Wongkham, S	1

Other Studies

1 other study(ies) available for sodium salicylate and Lymphoma, Primary Effusion

Article	Year
Potent reactive oxygen species-JNK-p38 activation by sodium salicylate potentiates death of primary effusion lymphoma cells. Anticancer research, 2014, Volume: 34, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Primary Effusion; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Sodium Salicylate	2014

Article

Year

Potent reactive oxygen species-JNK-p38 activation by sodium salicylate potentiates death of primary effusion lymphoma cells.

Anticancer research, 2014, Volume: 34, Issue:4

Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Primary Effusion; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Sodium Salicylate

2014